3 5 5 4 8

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊





更多详情 >>



会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

加入德孚官方微信,即可享受论文费用7.5折

视频

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

 

Authors Wang LY, Cui JJ, Guo AX, Yin JY

Received 28 September 2017

Accepted for publication 5 December 2017

Published 24 January 2018 Volume 2018:11 Pages 529—538

DOI https://doi.org/10.2147/OTT.S136579

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Carlos Vigil Gonzales

Abstract: Compared with various malignant tumors, lung cancer has high incidence and the highest mortality worldwide. Non-small-cell lung cancer (NSCLC), the most common kind of lung cancer, is still a great threat to the world, including China. Surgery, platinum-based chemotherapy, and radiotherapy are still the primary treatments for NSCLC patients in the clinic, whereas immunotherapy and targeted therapy are gradually playing more important roles. A next-generation tyrosine kinase inhibitor (TKI), afatinib, was developed as a targeted reagent for epidermal growth factor receptor (EGFR). This targeted drug was effective in a series of trials. The US Food and Drug Administration then approved afatinib as a new first-line treatment for EGFR L858R and exon 19 deletion mutant patients in 2013. This review focused on current clinical studies of afatinib. Although this TKI was not widely available in China until recently, we aim to provide a reference for its future use in China.
Keywords: afatinib, NSCLC, Chinese patients, drug resistance, side effect, companion diagnosis

 

摘要视频链接Afatinib in Chinese NSCLC patients